Patients facing a second mitral valve replacement now have two competing treatment paths, but clinicians lack definitive evidence to guide their choice between less invasive catheter-based procedures and traditional open-heart surgery. This knowledge gap affects thousands of patients whose original bioprosthetic valves deteriorate over time, typically requiring reintervention within 10-15 years.
The SURVIV trial will randomize 150 patients with failed mitral bioprostheses to receive either transcatheter mitral valve-in-valve replacement through a transseptal approach or conventional surgical redo replacement. The study's primary endpoint measures death or disabling stroke at 12 months, with secondary outcomes including major complications at 30 days and rehospitalization rates. Researchers will also monitor for prosthetic valve thrombosis and early structural deterioration at 3 and 12 months.
This head-to-head comparison addresses a critical gap in cardiovascular medicine, where transcatheter approaches have gained popularity despite limited randomized evidence. Previous observational studies suggest transcatheter procedures may reduce immediate surgical risks, particularly for high-risk patients, but questions remain about long-term durability and valve performance. The trial's design reflects current clinical uncertainty about optimal treatment selection criteria. For the aging population with increasing rates of valve replacement, this research could establish evidence-based treatment algorithms. However, the relatively small sample size may limit detection of meaningful differences in less common but serious complications, and the open-label design introduces potential bias in outcome assessment.